​

Illumina (ILMN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ILMN Stock Forecast

Illumina (ILMN) stock forecast, based on 50 Wall Street analysts, predicts a 12-month average price target of $115.25, with a high of $142.00 and a low of $100.00. This represents a -15.51% decline from the last price of $136.41.

$100 $109 $118 $127 $136 $145 High: $142 Avg: $115.25 Low: $100 Last Closed Price: $136.41

ILMN Stock Rating

Illumina stock's rating consensus is Buy, based on 50 Wall Street analysts. The breakdown includes 1 Strong Buy (2.00%), 24 Buy (48.00%), 19 Hold (38.00%), 6 Sell (12.00%), and 0 Strong Sell (0.00%).

Buy
Total 50 6 19 24 1 Strong Sell Sell Hold Buy Strong Buy

ILMN Price Target Upside V Benchmarks

TypeNameUpside
StockIllumina-15.51%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks6.89%

Price Target Trends

1M3M12M
# Anlaysts-719
Avg Price Target-$111.86$118.26
Last Closing Price$136.41$136.41$136.41
Upside/Downside--18.00%-13.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 251791220
Nov, 251791220
Oct, 2517101221
Sep, 2527101222
Aug, 2537101223
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2025Vijay KumarEvercore ISI$142.00$121.5916.79%4.10%
Oct 31, 2025Robert W. Baird$109.00$115.78-5.86%-20.09%
Oct 31, 2025UBS$120.00$115.783.64%-12.03%
Oct 31, 2025Canaccord Genuity$112.00$99.0113.12%-17.89%
Oct 31, 2025Luke SergottBarclays$100.00$99.011.00%-26.69%
Oct 24, 2025Robert W. Baird$105.00$99.975.03%-23.03%
Oct 02, 2025Barclays$95.00$102.26-7.10%-30.36%
Sep 02, 2025RBC Capital$124.00$97.8226.76%-9.10%
Aug 04, 2025Morgan Stanley$105.00$98.446.66%-23.03%
Aug 04, 2025Stephens$110.00$98.4411.74%-19.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2025Evercore ISIOutperformOutperformhold
Oct 31, 2025Cowen & Co.HoldHoldhold
Oct 31, 2025UBSNeutralNeutralhold
Oct 31, 2025BarclaysUnderweightUnderweighthold
Oct 02, 2025BarclaysUnderweightUnderweighthold
Aug 04, 2025StephensOverweightOverweighthold
Jul 11, 2025ScotiabankSector OutperformSector Performdowngrade
Jun 24, 2025BarclaysUnderweightUnderweighthold
May 15, 2025Piper SandlerOverweightOverweighthold
Mar 11, 2025BarclaysUnderweightUnderweighthold

Financial Forecast

EPS Forecast

$-30 $-22 $-14 $-6 $2 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.46$5.08$-28.05$-7.35$-7.69----
Avg Forecast$4.28$5.56$2.23$0.73$4.12$4.44$5.15$5.85$6.61
High Forecast$4.35$5.65$2.29$0.87$4.13$4.58$6.35$7.43$6.67
Low Forecast$4.19$5.44$2.18$0.62$4.09$4.33$3.56$4.75$6.53
Surprise %4.21%-8.63%-1357.85%-1106.85%-286.65%----

Revenue Forecast

$3B $4B $4B $5B $5B $6B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.24B$4.53B$4.58B$4.50B$4.37B----
Avg Forecast$3.19B$4.45B$4.57B$4.46B$4.33B$4.44B$4.68B$4.98B$5.25B
High Forecast$3.23B$4.51B$4.67B$4.49B$4.36B$4.47B$4.69B$4.99B$5.29B
Low Forecast$3.14B$4.38B$4.49B$4.44B$4.32B$4.40B$4.67B$4.96B$5.20B
Surprise %1.57%1.66%0.24%0.88%0.92%----

Net Income Forecast

$-5B $-3B $-2B $-900M $300M $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$656.00M$762.00M$-4.40B$-1.16B$-1.22B----
Avg Forecast$521.95M$878.46M$554.35M$-1.16B$649.63M$704.41M$679.88M$841.27M$1.04B
High Forecast$626.34M$892.13M$665.22M$-928.80M$652.79M$724.31M$1.00B$1.17B$1.05B
Low Forecast$417.56M$860.23M$443.48M$-1.39B$646.47M$684.51M$562.33M$750.97M$1.03B
Surprise %25.68%-13.26%-894.45%--288.26%----

ILMN Forecast FAQ

Is Illumina stock a buy?

Illumina stock has a consensus rating of Buy, based on 50 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 24 Buy, 19 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that Illumina is a favorable investment for most analysts.

What is Illumina's price target?

Illumina's price target, set by 50 Wall Street analysts, averages $115.25 over the next 12 months. The price target range spans from $100 at the low end to $142 at the high end, suggesting a potential -15.51% change from the previous closing price of $136.41.

How does Illumina stock forecast compare to its benchmarks?

Illumina's stock forecast shows a -15.51% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (6.89%).

What is the breakdown of analyst ratings for Illumina over the past three months?

  • December 2025: 5.00% Strong Buy, 35.00% Buy, 45.00% Hold, 5.00% Sell, 10.00% Strong Sell.
  • November 2025: 5.00% Strong Buy, 35.00% Buy, 45.00% Hold, 5.00% Sell, 10.00% Strong Sell.
  • October 2025: 4.76% Strong Buy, 33.33% Buy, 47.62% Hold, 4.76% Sell, 9.52% Strong Sell.

What is Illumina’s EPS forecast?

Illumina's average annual EPS forecast for its fiscal year ending in December 2025 is $4.44, marking a -157.74% decrease from the reported $-7.69 in 2024. Estimates for the following years are $5.15 in 2026, $5.85 in 2027, and $6.61 in 2028.

What is Illumina’s revenue forecast?

Illumina's average annual revenue forecast for its fiscal year ending in December 2025 is $4.44B, reflecting a 1.50% increase from the reported $4.37B in 2024. The forecast for 2026 is $4.68B, followed by $4.98B for 2027, and $5.25B for 2028.

What is Illumina’s net income forecast?

Illumina's net income forecast for the fiscal year ending in December 2025 stands at $704.41M, representing a -157.60% decrease from the reported $-1.223B in 2024. Projections indicate $679.88M in 2026, $841.28M in 2027, and $1.04B in 2028.